INTRODUCTION
============

Cardiac arrhythmias are major causes of morbidity and mortality ([@bib10]), with atrial fibrillation, the most prevalent cardiac arrhythmia, being a major risk factor for stroke ([@bib61]). Amiodarone is the most commonly prescribed antiarrhythmic drug owing to its efficacy and minimal proarrhythmic side effects ([@bib87]). Amiodarone acts through multiple mechanisms---prolongation of repolarization, reduction of excitability, and slowing of conduction ([@bib77])---exerting these effects by altering the function of diverse membrane proteins: ion channels, ion exchangers, and adrenergic receptors ([@bib35]). This multi-target therapeutic mechanism is a feature shared by other antiarrhythmics in current use ([@bib19]; [@bib30]), suggesting that a multipronged mechanism of action may be a desired feature of antiarrhythmic drugs, although the mechanism for such target promiscuity is unclear.

In the case of membrane proteins, the concurrent regulation of many different proteins could be caused by a common mechanism arising from drug-dependent changes in lipid bilayer properties that alter the energetic coupling between membrane proteins and their host bilayer ([@bib71]). This bilayer-mediated mechanism results from hydrophobic coupling between membrane proteins and the surrounding lipid bilayer ([@bib56]).

The lipid bilayer adaptation to a membrane protein's hydrophobic domain has an associated energetic cost, the bilayer deformation energy ($\Delta G_{\text{def}}^{0}$), which varies with changes in protein shape and lipid bilayer properties ([@bib65]; [@bib64]; [@bib66]). Different protein conformations (e.g., [@bib55]) are thus likely to be associated with different $\Delta G_{\text{def}}^{0}$ ([Fig. 1 A](#fig1){ref-type="fig"}). This concept is important because the free energy cost ($\Delta G_{\text{total}}^{\text{I}\rightarrow\text{II}}$) for a conformational change (between states I and II) is determined by the contributions from the membrane protein ($\Delta G_{\text{protein}}^{\text{I}\rightarrow\text{II}}$) and the bilayer ($\Delta G_{\text{bilayer}}^{\text{I}\rightarrow\text{II}} = \Delta G_{\text{def}}^{\text{II}} - \Delta G_{\text{def}}^{\text{I}}$) (e.g., [@bib55]):$$\Delta G_{\text{total}}^{\text{I}\rightarrow\text{II}} = \Delta G_{\text{protein}}^{\text{I}\rightarrow\text{II}} + \left( {\Delta G_{\text{def}}^{\text{II}} - \Delta G_{\text{def}}^{\text{I}}} \right) = \Delta G_{\text{protein}}^{\text{I}\rightarrow\text{II}} + \Delta G_{\text{bilayer}}^{\text{I}\rightarrow\text{II}},$$where $\Delta G_{\text{def}}^{\text{I}}$ and $\Delta G_{\text{def}}^{\text{II}}$ vary with changes in bilayer elasticity, thickness, and intrinsic lipid curvature ([@bib5]), which in turn means that $\Delta G_{\text{bilayer}}^{\text{I}\rightarrow\text{II}}$ (and therefore $\Delta G_{\text{total}}^{\text{I}\rightarrow\text{II}}$) will vary with changes in bilayer properties (except when the changes in $\Delta G_{\text{def}}^{\text{II}}$ equal the changes in $\Delta G_{\text{def}}^{\text{I}}$).

![A schematic illustration of how amphiphilic drugs can modulate membrane protein function by a bilayer-mediated mechanism and structures of the antiarrhythmics. (A) Schematic representation of the bilayer-mediated regulation of membrane protein function, which arises because the reversible partitioning of the amphiphiles between the aqueous solution and the bilayer--solution interface alters lipid bilayer properties, including the elasticity ([@bib21]; [@bib86]; [@bib15]) and thus Δ*G*~def~ (and therefore $\Delta G_{\text{bilayer}}^{\text{I}\rightarrow\text{II}}$). In the figure, conformations I and II are denoted as "closed" and "open," respectively. (B) Molecular structures of the antiarrhythmics amiodarone, dronedarone, propranolol, and pindolol.](JGP_201511470_Fig1){#fig1}

Drug-induced changes in lipid bilayer properties thus will shift a protein's conformational distribution by changing $\Delta G_{\text{bilayer}}^{\text{I}\rightarrow\text{II}},$ thereby producing changes in protein function ([Fig. 1 B](#fig1){ref-type="fig"}). Such bilayer-mediated regulation is exemplified, for example, in the effects of amphiphiles on voltage-gated sodium (Na~V~) channels ([@bib53]; [@bib71]; [@bib41]), mechanosensitive MscL, voltage-gated potassium (K~V~2.1) channels ([@bib41]), and the proton-gated prokaryotic potassium channel KcsA ([@bib72]). Importantly, because $\Delta G_{\text{bilayer}}^{\text{I}\rightarrow\text{II}} = \Delta G_{\text{def}}^{\text{II}} - \Delta G_{\text{def}}^{\text{I}},$ the relative changes in function will vary among membrane proteins.

We used gramicidin (gA) channels to quantify how amiodarone, dronedarone, propranolol, and pindolol ([Fig. 1 C](#fig1){ref-type="fig"}) alter $\Delta G_{\text{bilayer}}^{\text{M}\rightarrow\text{D}}.$ The bilayer deformation resulting from channel formation makes gA channels powerful probes because changes in the gA monomer↔dimer equilibrium, as reflected in changes in channel activity, can be directly related to changes in bilayer properties, making it possible to quantify $\Delta\Delta G_{\text{bilayer}}^{\text{M}\rightarrow\text{D}} = \Delta G_{\text{bilayer}}^{\text{M}\rightarrow\text{D}}\left( \text{drug} \right) - \Delta G_{\text{bilayer}}^{\text{M}\rightarrow\text{D}}\left( \text{no\ drug} \right)$ ([@bib55]).

Using a gA-based fluorescence assay (GBFA), we determined the bilayer-modifying potency of each drug ([@bib39]) and used gA single-channel electrophysiology ([@bib55]; [@bib71]) to obtain detailed information about which bilayer properties are affected and $\Delta\Delta G_{\text{bilayer}}^{\text{M}\rightarrow\text{D}}.$ We examined whether the antiarrhythmics alter the properties of bilayers formed from either 1,2-dioleoyl-*sn*-glycero-3-phosphocholine (DC~18:1~PC) or the ternary DC~18:1~PC/bovine sphingomyelin/cholesterol (DC~18:1~PC/porcine brain sphingomyelin \[bSM\]/Chol) mixture that mimics the cell membrane outer leaflet. All the antiarrhythmics tested alter lipid bilayer properties, with amiodarone and dronedarone doing so at clinically relevant concentrations. Our results show that, in addition to direct effects on specific targets, amiodarone and dronedarone may alter the function of diverse membrane proteins by a general bilayer-mediated mechanism.

MATERIALS AND METHODS
=====================

Materials
---------

DC~18:1~PC, 1,2-dierucoyl-*sn*-glycero-3-phosphocholine (DC~22:1~PC), bSM, and plant cholesterol were from Avanti Polar Lipids, Inc. Dronedarone, amiodarone, propranolol, pindolol (all ≥98% pure), and sodium thiosulfate (Na~2~S~2~O~3~; 99.999% pure) were from Sigma-Aldrich. Iodine (I~2~; 99.8% pure) was from VWR International. 8-Aminonaphthalene-1,3,6-trisulfonate (ANTS) was from Invitrogen. The gA analogues \[Ala^1^\]gA and gA(15), and the sequence-shortened, left-handed des-d-Val-Gly-gA^−^ and gA^−^(13), used for the single-channel experiments, were synthesized and purified as described previously ([@bib28]; see sequences in [Table S1](http://www.jgp.org/cgi/content/full/jgp.201511470/DC1){#supp1}). The gA used in the fluorescence quench experiments was the naturally occurring mixture, which is 80--85% gA plus gAs B and C ([@bib1]). (The mixture is often called gA D \[gD\] after R. Dubos, who discovered the gAs \[[@bib20]\].)

GBFA
----

Large unilamellar vesicles (LUVs) were made from DC~22:1~PC as described in [@bib39], with the following modifications. Phospholipids in chloroform and gD in methanol (1,000:1 lipid/gA weight ratio) were mixed, the chloroform and methanol were evaporated under nitrogen stream, and the lipid/gD mix was left overnight in a desiccator under vacuum to remove trace amounts of solvent. Because of the inevitable variation in LUV sizes, the time course of the fluorescence quenching cannot be described by a single-exponential decay, and the quench rates were obtained by fitting a stretched exponential ([@bib11]):$$F\left( t \right) = F\left( \infty \right) + \left( {F\left( 0 \right) - F\left( \infty \right)} \right) \cdot \exp\left\{ {- \left( {t/\tau_{0}} \right)^{\beta}} \right\}$$to the fluorescence quench time course from each mixing reaction (where *F*(*t*) and *F*(0) denote the fluorescence at times *t* and 0, respectively; τ~0~ is a parameter with the dimensions of time; and β, the parameter that defines the deviation from the single exponential, is 0 \< β ≤ 1) and evaluating the quench rate at 2 ms (the instrumental dead time is ∼1.5 ms):$$k\left( t \right) = \left( {\beta/\tau_{0}} \right)\left. {\cdot \left( {t/\tau_{0}} \right)} \right|_{2\text{ms}}.$$

To test the drugs' bilayer-modifying potency, we added aliquots of 50--100-mM stock solutions of the drugs in DMSO---dronedarone, amiodarone (±Na~2~S~2~O~3~), propranolol, pindolol, as well as iodine (±Na~2~S~2~O~3~)---and incubated the LUVs with the drug in question for 10 min at 25°C before determining the fluorescence quench time courses. The DMSO concentration did not exceed 0.5% (vol/vol), a concentration at which it does not alter lipid bilayer properties ([@bib39]). Each measurement consisted of (four to eight) individual mixing reactions, and the rates for each mixing reaction were averaged and normalized to the control rate in the absence of drug.

Single-channel gA current measurements
--------------------------------------

gA single-channel recordings were done at 25°C using the bilayer punch method ([@bib3]; [@bib71]). In brief, planar bilayers were formed from DC~18:1~PC in *n*-decane or a DC~18:1~PC/bSM/Chol in *n*-decane across a hole in a Teflon partition that separated two 1.0-M NaCl (buffered to pH 7.0 with HEPES), as described previously ([@bib28]; [@bib71]). The membranes were doped with gA(15) and gA^−^(13), and control channel activity was recorded after a 30-min equilibration. Aliquots of 10--100-mM DMSO stock solutions of dronedarone, amiodarone (±Na~2~S~2~O~3~), propranolol, pindolol, and I~2~ (in H~2~O) were then added to both sides of the bilayer; the solutions were equilibrated with the membrane for 10 min before recording. DMSO did not exceed 1% (vol/vol), a concentration that has no effect on gA channel function ([@bib39]). Appearance frequencies (*f*) were determined only if the bilayer remained intact for the duration of the entire experiment (before and after drug addition). The number of gA channel events from one to two recordings before drug addition was determined from the number of channel appearances obtained from the analysis of single-channel lifetimes and divided by the total recording time (≥5 min) to give the control *f*~cntrl~. If the bilayer remained intact, in a similar procedure to the one above, *f*~drug~ was determined from one to two recordings immediately after a 10-min equilibration with the drug. Single-channel lifetimes (τ) were determined by fitting survivor histograms with a single-exponential distribution (*N*(*t*)/*N*(0) = exp\[−*t*/τ\], where *N*(*t*) is the number of channels with lifetime longer than time *t*) using Origin 6.1 (OriginLab). The results represent mean ± SD (*n* = 2--4) or mean ± range (for *n* = 2). Relative changes in bilayer deformation energy were calculated as ([@bib7]; [@bib71]):$$\Delta\Delta G_{\text{bilayer}}^{\text{M}\rightarrow\text{D}} \approx - k_{\text{B}}T \cdot \text{ln}\left\{ {{\tau_{\text{drug}} \cdot f_{\text{drug}}}/\left( {\tau_{\text{cntrl}} \cdot f_{\text{cntrl}}} \right)} \right\},$$where *f*~drug~ and τ~drug~ denote the gA channel appearance frequency and lifetime in the presence of an antiarrhythmic.

Online supplemental material
----------------------------

Fig. S1 plots the relative changes in gA^−^(13) and gA(15) τ and *f* with increasing concentrations of amiodarone, dronedarone, propranolol, and pindolol. Fig. S2 shows effects of antiarrhythmics on gA^−^(13) and gA(15) current transition amplitude. Fig. S3 (A and B) shows changes in $\Delta\Delta G_{\text{bilayer}}^{\text{M}\rightarrow\text{D}}$ and gA^−^(13) and gA(15) current transition amplitudes as a function of antiarrhythmic mole fraction in the bilayer. Fig. S3 C plots changes in $\Delta\Delta G_{\text{bilayer}}^{\text{M}\rightarrow\text{D}}$ as a function of changes in gA^−^(13) and gA(15) current transition amplitudes. Fig. S4 shows time dependence of changes in gA^−^(13) and gA(15) τ by amiodarone in the absence and presence of Na~2~S~2~O~3~, which reduces I~2~ to I^−^. Fig. S5 shows absence of amiodarone-effect time dependence in GBFA experiments. Table S1 lists the sequence and channel hydrophobic length of gA analogues used in this study. The online supplemental material is available at <http://www.jgp.org/cgi/content/full/jgp.201511470/DC1>.

RESULTS
=======

Effects of antiarrhythmics on lipid bilayer properties
------------------------------------------------------

We tested the bilayer-modulating effects of amiodarone, propranolol, and pindolol at concentrations where they have acute effects on cardiac excitability ([@bib46]; [@bib35]) and alter sarcolemmal enzyme activities ([@bib18]), and dronedarone at its clinical concentrations ([Table 1](#tbl1){ref-type="table"}) using the GBFA.

###### 

Nominal and free antiarrhythmic concentrations

  Antiarrhythmic   Clinical plasma concentrations (µM)          LogP[a](#tblfn1){ref-type="table-fn"}   *m*~m~[b](#tblfn2){ref-type="table-fn"}          
  ---------------- -------------------------------------------- --------------------------------------- ----------------------------------------- ------ --------------
                                                                Experimental concentrations (µM)                                                         
                                                                Nominal                                 Free                                             
  Dronedarone      0.15--0.3[c](#tblfn3){ref-type="table-fn"}   10                                      7 × 10^−5^                                8.75   4.0 × 10^−2^
  Amiodarone       1[d](#tblfn4){ref-type="table-fn"}           30                                      1 × 10^−3^                                7.8    10^−1^
  Propranolol      0.01--1[e](#tblfn5){ref-type="table-fn"}     200                                     90                                        3.48   2.5 × 10^−1^
  Pindolol         0.04[f](#tblfn6){ref-type="table-fn"}        300                                     300                                       1.75   1.5 × 10^−2^

[@bib9].

Estimated following [@bib14], [@bib40], and [@bib71].

[@bib34].

[@bib31], [@bib48], and [@bib75].

[@bib85], [@bib83], and [@bib75].

[@bib16] and [@bib58].

The GBFA takes advantage of gA channels' permeability to Tl^+^, a quencher of the water-soluble fluorophore ANTS, where the rate of influx is a function of the time-averaged number of gA channels in the LUV membrane ([@bib39]). In the absence of gA (top horizontal traces in [Fig. 2 A](#fig2){ref-type="fig"}), the drugs have no effect on the rate of fluorescence quenching, meaning that the compounds did not compromise lipid bilayer stability at the concentrations tested. In the presence of the drugs, the gA-dependent fluorescence quench rate increases (bottom traces in [Fig. 2 A](#fig2){ref-type="fig"}), demonstrating that the antiarrhythmics increase the rate of Tl^+^ influx into the LUVs. This increase is caused by a shift in the gA monomer↔dimer equilibrium toward the conducting dimer state as antiarrhythmics decrease $\Delta G_{\text{bilayer}}^{\text{M}\rightarrow\text{D}}$ and thereby the free energy of dimerization ([@bib5]):$$\frac{\left\lbrack \text{D} \right\rbrack}{\left\lbrack \text{M} \right\rbrack^{2}} = K^{\text{M}\rightarrow\text{D}} = \exp\left\{ \frac{\Delta G_{\text{protein}}^{\text{M}\rightarrow\text{D}} + \Delta G_{\text{bilayer}}^{\text{M}\rightarrow\text{D}}}{k_{\text{B}}T} \right\}.$$The relative potency of each antiarrhythmic was quantified by plotting the change in quench rate (normalized to the rate in the absence of drug) as a function of drug concentration ([Fig. 2 B](#fig2){ref-type="fig"}).

![Antiarrhythmics alter lipid bilayer properties. (A, left) Fluorescence quench traces showing Tl^+^ quenching of ANTS fluorescence in DC~22:1~PC LUVs without gA (−gA; the top two traces) and with gA (+gA; the bottom five traces) in the absence of drug (black, control) or with dronedarone (green), amiodarone (orange), propranolol (cyan), and pindolol (purple). Amiodarone, dronedarone, and propranolol increase the fluorescence signal up to 12% depending on the concentration, but the flux rate measurements were not affected. The results for each drug represent five to eight repeats (dots) and their averages (solid lines). (Right) Single repeats (dots) with stretched exponential fit (solid line). (B) Normalized quench rates determined from the stretched exponential fits at varying antiarrhythmic concentrations. Error bars represent mean ± SD (*n* = 3 -- 5).](JGP_201511470_Fig2){#fig2}

The antiarrhythmics decreased $\Delta G_{\text{bilayer}}^{\text{M}\rightarrow\text{D}}$ with rank order: dronedarone ≥ amiodarone \> propranolol \> pindolol.

The concentrations used in [Fig. 2](#fig2){ref-type="fig"} are the nominal concentrations, which are not corrected for drug distribution between the aqueous and membrane phases. We estimated the aqueous concentrations following [@bib14] using measured partition coefficients into lipid bilayers, LogP, and compared those to the free plasma concentrations at therapeutic doses ([Table 1](#tbl1){ref-type="table"}). The free concentrations of amiodarone and dronedarone, the most hydrophobic compounds, are comparable to the clinical concentrations, whereas the free concentrations of the less hydrophobic propranolol and pindolol are orders of magnitude higher than the clinical concentrations ([@bib2]; [@bib85]), although there is overlap between the concentration range where propranolol alters lipid bilayer properties and the concentration range where it alters the function of voltage-dependent sodium channels ([@bib81]).

The lipid bilayer--modifying potency of the tested antiarrhythmics need not scale with the compounds' bilayer-partitioning coefficient ([@bib14]; [@bib71]). At the given partitioning coefficient and concentration, antiarrhythmics reach varying mole fraction in the membrane ([Table 1](#tbl1){ref-type="table"}, *m*~m~) to achieve similar magnitudes of bilayer-modifying effects ([Fig. 2 B](#fig2){ref-type="fig"}), where dronedarone requires approximately an order of magnitude lower *m*~m~ than propranolol for comparable effects; to achieve a comparable effect with pindolol would require a much higher *m*~m~ than for the other compounds.

Antiarrhythmics increase bilayer elasticity, which contributes to the decrease in Δ*G*~bilayer~
-----------------------------------------------------------------------------------------------

To determine what bilayer properties the antiarrhythmics alter, we determined the effects on the average single-channel lifetimes (τ), appearance frequencies (*f*), and current transition amplitudes (compare [@bib5]; [@bib55]; [@bib71]). The gA single-channel τ is the inverse of the gA dimer dissociation rate constant, and *f* is proportional to monomer association rate constant. Changes in τ and *f* in the presence of a bilayer-modifying amphiphile reflect the amphiphile's effect on the bilayer deformation energy, and the relative changes in τ and *f* allow us to estimate the amphiphile-induced change in the bilayer deformation energy, ΔΔG~bilayer~ ([Eq. 4](#fd4){ref-type="disp-formula"}). Because the experiments were done with gA analogues of different lengths, the 15--amino acid gA(15) and the enantiomeric, sequence-shortened analogue gA^−^(13), respectively, which form channels of different lengths (Table S1) and thus different bilayer-channel hydrophobic mismatches. Consequently, if a drug alters bilayer elasticity, the magnitude of the resulting changes in τ and *f* will be larger for the channels with the larger hydrophobic mismatch (in this case those formed by the gA^−^(13) subunits). Conversely, if the changes in bilayer deformation are similar for channels of different length, the drugs have minimal effects on bilayer elasticity.

All the antiarrhythmics increased τ and *f* ([Figs. 3 A](#fig3){ref-type="fig"} and [S1](http://www.jgp.org/cgi/content/full/jgp.201511470/DC1){#supp2}, and [Table 2](#tbl2){ref-type="table"}). The initial experiments with amiodarone showed a time-dependent increase in channel activity ([Fig. S4](http://www.jgp.org/cgi/content/full/jgp.201511470/DC1){#supp3}), which we surmised might be caused by the iodine in amiodarone. We therefore did experiments in which we added Na~2~S~2~O~3~, which reduces I~2~ to I^−^ ([@bib23]), together with the amiodarone. Na~2~S~2~O~3~ did indeed abolish the time-dependent increase in channel activity (lifetime), but the effect of amiodarone could not be mimicked by adding I~2~ (Fig. S4, legend). In any case, all the experiments with amiodarone were done in the presence of 50 µM Na~2~S~2~O~3~. Dronedarone and amiodarone produced larger changes in τ and *f* for the shorter gA^−^(13) channels, as compared with the longer gA(15) channels; within experimental error, propranolol and pindolol produced similar changes in τ and *f* for both channels ([Table 2](#tbl2){ref-type="table"} and Fig. S1).

###### 

Relative increases in the antiarrhythmic-induced gA channel appearance frequencies and lifetimes

  gA single-channel properties   Amiodarone   Dronedarone   Propranolol   Pindolol                                                                               
  ------------------------------ ------------ ------------- ------------- ----------- ----------- ------------ ------------ ------------ ----------- ----------- -----------
  *f*~13~/*f*~13cntrl~           2.5 ± 0.7    6.5 ± 0.3     2.1 ± 0.1     4.2 ± 1.2               1.6 ± 0.4    4.4 ± 0.3    9            3 ± 1       4.0 ± 1.2   5
  *f*~15~/*f*~15cntrl~           3.1 ± 0.5    3.6 ± 1.2     1.7 ± 0.03    2.2 ± 0.7               1.8 ± 0.6    6.5 ± 0.2    11           2.2 ± 0.4   3.4 ± 1.1   4
  τ~13~/τ~13cntrl~               1.6 ± 0.2    3.5 ± 0.2     1.5 ± 0.1     2.2 ± 0.2   4.6 ± 0.8   1.1 ± 0.1    1.2 ± 0.03   1.8 ± 0.2    1.0 ± 0.1   1.1 ± 0.1   1.4 ± 0.3
  τ~15~/τ~15cntrl~               1.5 ± 0.3    2.3 ± 0.04    1.2 ± 0.1     1.6 ± 0.3   3.0 ± 0.8   1.0 ± 0.05   1.1 ± 0.1    1.4 ± 0.02   1.1 ± 0.1   1.2 ± 0.2   1.3 ± 0.1

Values represent relative changes in gA channels' single-channel appearance frequencies (*f*) and lifetimes (τ), where *f* or τ in the presence of antiarrhythmics is normalized to that in the absence of antiarrhythmic in the same experiment.

Knowing the relative changes in τ and *f* ([Table 2](#tbl2){ref-type="table"}), we can estimate the changes in Δ*G*~bilayer~ following [@bib7], [@bib5], [@bib55], [@bib71], [Eq. 4](#fd4){ref-type="disp-formula"}, and [Fig. 3 B](#fig3){ref-type="fig"}. All the antiarrhythmics decreased Δ*G*~bilayer~, with dronedarone being the most, and pindolol the least, potent, whether they increased or decreased membrane fluidity ([@bib17]).

![Antiarrhythmics increase gA single-channel activity and decrease the bilayer deformation energy ($\Delta\Delta G_{\text{bilayer}}^{\text{M}\rightarrow\text{D}}$). (A) gA single-channel traces without (top row) and with (bottom row) the antiarrhythmics at the indicated concentrations; red and blue dashed lines indicate the average gA^−^(13) and gA(15) single-channel current amplitudes. (B) Changes in $\Delta\Delta G_{\text{bilayer}}^{\text{M}\rightarrow\text{D}},$ which were estimated from the ratio of the time-averaged number of gA channels in the presence (τ~drug~ · *f*~drug~) and absence (τ · *f*) of the antiarrhythmic (compare [Eq. 4](#fd4){ref-type="disp-formula"}). Blue symbols denote results for gA(15) channels, and red symbols denote results for gA^−^(13) channels. Error bars represent mean ± SD, if *n* ≥ 3; mean ± range/2, if *n* = 2.](JGP_201511470_Fig3){#fig3}

Confirming previous studies ([@bib56]; [@bib71]), structurally diverse compounds produce remarkably similar relative increases in the lifetimes of the short gA^−^(13) channels relative to the long gA(15) channels. [Fig. 4 A](#fig4){ref-type="fig"} shows the linear relation between the natural logarithms of the changes in τ for the short gA^−^(13) channels ln\[τ~13/~τ~13cntrl~\] versus the changes for the long gA(15) channels ln\[τ~15/~τ~15cntrl~\], where we included earlier results from [@bib71] and [@bib41].

![The antiarrhythmic-induced changes in the single-channel lifetimes of gA^−^(13) channels versus the changes in the lifetimes of gA(15) channels. (A) Natural logarithm of relative changes in τ~13~ (ln(τ~13~/τ~13cntrl~)) versus the natural logarithm of relative changes in τ~15~ (ln(τ~15~/τ~15cntrl~)) observed for dronedarone (green), amiodarone (orange circle), propranolol (blue triangle), and pindolol (black square) plotted together with results from [@bib56] and [@bib71]. The points cluster around a straight line with slope 1.2 ± 0.03 (error bars represent mean ± SE). (B) Distribution of the slopes for the lnτ~13~ versus lnτ~15~ relations for the individual compounds in A. The distribution is fit by Gaussian function with a mean ± SD (σ calculated from the fit) of 1.3 ± 0.2, σ = 0.3. Changes in the histogram bin size result in the median slope ranging between 1.2 and 1.3. Inset illustrates an individual linear fit to the (ln(τ~13~/τ~13cntrl~)) versus ln(τ~15~/τ~15cntrl~) in the presence of dronedarone (green symbols). Slopes of the linear fits, such as that in the inset, obtained for each compound were used to construct the distribution in B.](JGP_201511470_Fig4){#fig4}

The overall similarity among the ln\[τ~13~/τ~13,cntrl~\] versus ln\[τ~15~/τ~15,cntrl~\] relations for different compounds, together with the similar effects on left- and right-handed channels (the channels formed by gA^−^(13) and gA(15) have opposite chirality), shows that the changes in gA activity primarily are caused by changes in general bilayer properties that are insensitive to the structural characteristics of the compounds, as opposed to direct interactions with gA itself. The slope of the ln\[τ~13~/τ~13,cntrl~\] versus ln\[τ~15~/τ~15,cntrl~\] relation is 1.20 ± 0.03 (lower and upper confidence limits: 1.14 and 1.25), regardless of the particular compound's bilayer-modifying potency ([Fig. 4 A](#fig4){ref-type="fig"}). Focusing on the individual antiarrhythmics, the slopes of the ln\[τ~13~/τ~13,cntrl~\] versus ln\[τ~15~/τ~15,cntrl~\] relationships are: 1.3 ± 0.2 for dronedarone, 1.5 ± 0.1 for amiodarone, 1.5 ± 0.3 for propranolol ([Fig. 4 B](#fig4){ref-type="fig"}, inset), and 1.1 ± 0.3 for pindolol. In the case of propranolol, however, given the miniscule changes in τ ([Table 2](#tbl2){ref-type="table"} and Fig. S1), slope of the ln\[τ~13~/τ~13,cntrl~\] versus ln\[τ~15~/τ~15,cntrl~\] relation does not differ from 1. A histogram of individual slopes can be fit with a Gaussian with a mean of 1.30 ± 0.02, σ = 0.3 ([Fig. 4 B](#fig4){ref-type="fig"}), suggesting that there may be additional compound structure--dependent effects on the lipid bilayer, because of their varying effects on the acyl chain packing and dynamics in the bilayer core, in addition to the increase in bilayer elasticity that arises for thermodynamic reasons ([@bib21]; [@bib63]; [@bib15]).

In addition to the changes in τ and *f*, the antiarrhythmics reduced the current transition amplitudes of both gA(15) and gA^−^(13) channels ([Fig. S2](http://www.jgp.org/cgi/content/full/jgp.201511470/DC1){#supp4}). The changes in current transition amplitudes most likely arise because charged amphiphiles that adsorb to the bilayer--water interface in the vicinity of a gA channel will impart a surface potential that will alter the local ion concentrations and thus the single-channel current amplitude transitions ([@bib6]; [@bib51]; [@bib14], [@bib15]; [@bib71]). The antiarrhythmics are secondary and tertiary amines with pKs of ∼9, and will thus impart a positive surface charge when they partition into the membrane--solution interface at pH 7.0 ([@bib24]). The positive charge will reduce the cation concentration near the pore entrance, which would account for the reduction in current transition amplitudes, which is opposite to the increases that were observed with the negatively charged polyunsaturated fatty acid, docosahexaenoic acid, which increases the current transition amplitudes ([@bib15]). We cannot completely rule out the possibility that the antiarrhythmics interact directly with gA channels, but the similar effects on left- and right-handed channels, the correlation between the magnitude of the current transition amplitude reduction and the antiarrhythmic's LogP ([Table 1](#tbl1){ref-type="table"}), as well as the correlation between antiarrhythmic mole fractions at which the current transition amplitude shift occurs ([Fig. S3 A](http://www.jgp.org/cgi/content/full/jgp.201511470/DC1){#supp5}) and at which they decrease Δ*G*~bilayer~ (Fig. S3 B) all suggest that accumulation of surface charge is a primary determinant of the decreased current transition amplitudes. Plotting the changes in Δ*G*~bilayer~ as a function of the changes in current transition amplitude, (*i*~cntrl~ − *i*)/*i*~cntrl~ (Fig. S3 C), show that all the antiarrhythmics produce similar slopes in the Δ*G*~bilayer~ versus (*i*~cntrl~ *−* *i*)/*i*~cntrl~ relations for the gA(15) channels, indicating that the two parameters correlate and depend in a similar manner on the mole fraction of the compound in the bilayer. For the gA^−^(13) channels, the slopes of the Δ*G*~bilayer~ versus (*i*~cntrl~ *−* *i*)/*i*~cntrl~ relations for pindolol and propranolol are similar to those for gA(15), whereas the slopes for dronedarone and amiodarone are larger (as would be expected because dronedarone and amiodarone increase bilayer elasticity).

Experiments with ternary lipid bilayer mixtures
-----------------------------------------------

Experiments in DC~18:1~PC bilayers yield unambiguous information that can be used to calculate changes in the bilayer deformation energy caused by reversible partitioning ([@bib7]; [@bib5]; [@bib55]; [@bib71]) of drugs without the complications of domain reorganization and heterogeneous phospholipid mixing that may confound the quantification of effects on more complex bilayers. The bilayers of cell membranes, however, have complex lipid compositions ([@bib82]; [@bib79]). To explore whether the antiarrhythmics alter bilayer properties in bilayers with heterogenous lipid composition, where their effects could be dampened or obscured (or, maybe, enhanced) by lipid redistribution and changes in domain organization (e.g., [@bib32]; [@bib33]), we did experiments using DC~18:1~PC/bSM/Chol (1:1:1) mixtures, where there is coexistence of liquid-ordered and liquid-disordered domains ([@bib80]; [@bib8]; [@bib68]). If gA forms conducting dimers in both the liquid-ordered and liquid-disordered domains that have different properties (i.e., stiffness), we would expect this to differentially alter gA single-channel properties, which would be observed as two populations of channels with different average lifetimes (τ). We observe only a single, kinetically homogeneous channel population, however ([Fig. 5](#fig5){ref-type="fig"}). The parsimonious interpretation of these results is that $\Delta G_{\text{bilayer}}^{\text{M}\rightarrow\text{D}}$ in the stiffer liquid-ordered domains is so much larger than in the liquid-disordered domains (e.g., [@bib52]) that we observe gA channel activity only in the liquid-disordered domains---and that the antiarrhythmics do not soften the liquid-ordered domains sufficiently to allow for channel formation.

![Survivor single-channel lifetime histograms for gA(15) in DC~18:1~PC and DC~18:1~PC/bSM/Chol bilayers with single-exponential fits. There is no evidence for the existence of more than one population of channels in either membrane.](JGP_201511470_Fig5){#fig5}

Dronedarone produced similar changes in the reference DC~18:1~PC bilayers and in bilayers formed from DC~18:1~PC/bSM/Chol 1:1:1 ([Fig. 6](#fig6){ref-type="fig"}), as a mimic of the extracellular leaflet of the plasma membrane ([@bib22]). Dronedarone increased both τ and *f* for gA(15) channels over a similar concentration range as in DC~18:1~PC membranes, but to a greater extent ([Table 2](#tbl2){ref-type="table"} and Figs. S1 and [6, A and B](#fig6){ref-type="fig"}): at 3 µM dronedarone, ΔΔ*G*~bilayer~ was doubled from 5.2 kJ/mole in DC~18:1~PC to 10.5 kJ/mole in DC~18:1~PC/bSM/Chol (compare [Figs. 3 B](#fig3){ref-type="fig"} and [6 C](#fig6){ref-type="fig"}). The increased effect on ΔΔ*G*~bilayer~ most likely reflects that the liquid-ordered domains in the ternary mixture are stiffer than the DC~18:1~PC bilayers, which would lead to larger absolute changes in the amphiphile-induced changes in bilayer elasticity ([@bib15]). In any case, these results show that there are no qualitative differences in the antiarrhythmics' effects on single-component and multicomponent bilayers.

![Dronedarone alters gA(15) channel function in bilayers formed from ternary DC~18:1~PC/bSM/Chol 1:1:1 mixtures. (A) Relative changes in τ. (B) Relative changes in *f*. (C) The decrease in $\Delta\Delta G_{\text{bilayer}}^{\text{M}\rightarrow\text{D}}.$ Error bars represent mean ± range/2 (*n* = 2).](JGP_201511470_Fig6){#fig6}

DISCUSSION
==========

A hallmark of many current and in-development antiarrhythmics is their effects on numerous, diverse membrane proteins ([@bib77]; [@bib19]; [@bib87]), as is the case for amiodarone and dronedarone ([@bib46]; [@bib87]; [@bib34]). Although well established, the mechanism(s) underlying these multi-target effects remains unresolved. The prevailing paradigm attributes drug regulation of protein function to direct interactions (binding) of a drug to its target, but this paradigm does not readily explain the multi-targeting behavior over a narrow effective concentration range. So, alternatively, amiodarone and dronedarone could act through a common, more general mechanism such as drug-induced changes in the energetic coupling between the bilayer-embedded proteins and their host bilayer ([@bib73]; [@bib4]; [@bib44]; [@bib50]). To explore this possibility, we took advantage of the gA channels' sensitivity to changes in lipid bilayer properties to determine whether amiodarone and dronedarone, as well as propranolol and pindolol ([@bib18]), might alter the energetic coupling between a well-defined reporter channel and the host lipid bilayer.

Amiodarone and dronedarone alter lipid bilayer properties at their clinical, pharmacologically relevant ([@bib46]; [@bib87]; [@bib34]) concentrations ([Table 1](#tbl1){ref-type="table"}). In contrast, propranolol and pindolol block β-adrenergic receptors ([@bib87]) and have their clinical effects in the micromolar concentration range ([@bib2]; [@bib85]), which does not overlap with the concentrations at which they alter lipid bilayer properties ([Table 1](#tbl1){ref-type="table"}).

We first discuss the generality of drug-induced changes in lipid bilayer properties. We then consider how, despite the generality, different amphiphiles alter different bilayer properties and the time-dependent effects of amiodarone. We finally discuss the implications of our results for target promiscuity and a bilayer-dependent mechanism for polypharmacology.

Generality of amphiphile-induced changes in lipid bilayer properties
--------------------------------------------------------------------

Dronedarone is a more potent bilayer modifier in DC~18:1~PC/bSM/Chol 1:1:1 bilayers, producing a twofold larger reduction in $\Delta G_{\text{bilayer}}^{\text{M}\rightarrow\text{D}}$ than in DC~18:1~PC bilayers ([Figs. 3 B](#fig3){ref-type="fig"} and [6 C](#fig6){ref-type="fig"}). Similarly, we have shown previously that amphiphiles produce greater increases in gA channel activity in cholesterol-containing bilayers, as compared with cholesterol-free membranes ([@bib14]; [@bib71]). The increased effect in cholesterol-containing bilayers reflects that cholesterol increases bilayer thickness ([@bib76]; [@bib25]) and elastic moduli ([@bib62]), making it energetically more costly to deform cholesterol-containing bilayers ([@bib52]). The increased stiffness further causes the amphiphile-induced changes in bilayer stiffness to be increased ([@bib15]), which also contributes to the greater changes in channel function.

As is the case for other amphiphiles ([@bib54], [@bib56]; [@bib29]), all four antiarrhythmics produce greater relative changes in *f* than in τ, consistent with the notion that gA dimer formation involves a large decrease in local membrane thickness, whereas dimer dissociation involves only a modest axial separation of the monomers ([@bib37]; [@bib56]). This is evident also when comparing the effects of dronedarone on gA(15) in DC~18:1~PC and DC~18:1~PC/bSM/Chol bilayers. Indeed, 1 µM dronedarone increased *f* by a factor of 2.2 in DC~18:1~PC versus 12.7 in DC~18:1~PC/bSM/Chol bilayers; yet the relative changes in τ were only 1.6 versus 2.3, respectively ([Table 2](#tbl2){ref-type="table"} and Figs. S1 and [6, A and B](#fig6){ref-type="fig"}), reflecting the greater decrease in Δ*G*~bilayer~ (and greater stiffness) in the ternary mixture as compared with DC~18:1~PC bilayers ([Figs. 3 B](#fig3){ref-type="fig"} and [5 C](#fig5){ref-type="fig"}). Not surprisingly, therefore the Δ*G*~bilayer~ versus (*i*~cntrl~ *−* *i*)/*i*~cntrl~ relation for gA(15) channels in DC~18:1~PC/bSM/Chol bilayers is steeper than the relation in DC~18:1~PC bilayers (Fig. S3 C).

We conclude that amphiphiles alter lipid bilayer properties generally, but that the magnitude of the changes in Δ*G*~bilayer~ varies with changes in the membrane lipid composition. We further note that amphiphile-induced changes in integral membrane protein function are related to the changes in gA channel function in single-component bilayers ([@bib38]; [@bib54]; [@bib14]; [@bib40], [@bib41]; [@bib71]), and changes in (Na~V~) function in cell membranes scale with the changes in gA function in single-component bilayers ([@bib54]; [@bib71]; [@bib36]). That is, the results with gA channels in well-defined bilayer systems relate well to the results in the much more complex situation in cellular membranes, even though the conformational changes in membrane proteins are far more complex than the gA monomer↔dimer transitions. In either case, however, the bilayer deformation energies for the different states are functions of the same changes in bilayer properties, which allows for the use of gA channels as probes for changes in lipid bilayer properties and in membrane protein function.

What bilayer properties are altered by amphiphiles?
---------------------------------------------------

Amphiphile-induced changes in lipid bilayer properties ([@bib74]) have often been attributed to changes in bilayer fluidity (e.g., [@bib26]; [@bib18]), but changes in membrane fluidity per se cannot account for changes in the energetics of membrane protein conformational change or membrane protein function ([@bib49]). Moreover, apparent changes in fluidity may reflect changes in the free volume of the membrane, which would be proportional to changes in membrane tension ([@bib57]) and, using the polymer brush model ([@bib69]), also the elastic moduli. Increases in membrane tension increase gA activity by effectively reducing the hydrophobic mismatch ([@bib37]; [@bib27]). Indeed, [@bib18] found that amiodarone and propranolol alter bilayer fluidity in opposite directions but have similar effects on membrane protein function, which is not consistent with either changes in fluidity per se or changes in tension/bilayer thickness being the primary determinant of the changes in membrane protein function.

Amiodarone and dronedarone alter channel τ and *f* in a hydrophobic mismatch-dependent manner, indicating that amiodarone and dronedarone increase bilayer elasticity and thereby reduce the bilayer deformation energy associated with channel formation ([@bib54]; [@bib5]). Propranolol and pindolol, in contrast, produced similar increases in *f* and minimal increases in τ for the short gA^−^(13) and the long gA(15) channels ([Table 2](#tbl2){ref-type="table"} and Fig. S1), with the relative increases in *f* being larger than the increases in τ (pindolol produced no increase in τ). That is, propranolol and pindolol do not increase bilayer elasticity. Within the framework provided by the theory of elastic bilayer deformations, they alter the intrinsic curvature: positive changes in curvature will decrease $\Delta G_{\text{bilayer}}^{\text{M}\rightarrow\text{D}}$ ([@bib64]).

Time-dependent effects of amiodarone
------------------------------------

Chronic use of amiodarone is associated with toxicity ([@bib46]) and prolongation of action potential duration, presumably caused by decreased I~Ks~ and I~to~ current densities ([@bib47]; [@bib43]). The prevention of structural remodeling of the atria by chronic amiodarone is thought to result from gene expression regulation by amiodarone's antagonism of thyroid hormone (triiodothyronine) action on nuclear receptors ([@bib46]). Changes in mRNA levels for the channels responsible for I~Ks~ and I~to~, however, do not account for all the effects observed with chronic amiodarone ([@bib43]). Some of these effects may be caused by the iodine in amiodarone and the known toxicity of iodine ([@bib84]). Specifically, iodine can oxidize carbon--carbon double bonds in fatty acids ([@bib45]), for example, the oleic acid in DC~18:1~PC, and we sought to determine whether the time-dependent amiodarone effects (Fig. S4) could be caused by such changes in the acyl chains in DC~18:1~PC. Although amiodarone produced time-dependent increases in channel activity planar lipid bilayers (Fig. S4), it did not do so in LUVs ([Fig. S5](http://www.jgp.org/cgi/content/full/jgp.201511470/DC1){#supp6}), where the lipid/amiodarone ratio is 10-fold higher, which would tend to reduce the effect of any covalent changes in the acyl chains. More importantly, I~2~ alone did not mimic the effect of amiodarone in planar bilayers (Fig. S4, legend) or in LUVs (Fig. S5). It is not clear whether the time-dependent effects of amiodarone on planar lipid bilayers could underlie some of its pharmacologic/toxic effects during chronic use.

Target-promiscuity and bilayer-mediated mechanisms for altering membrane protein function
-----------------------------------------------------------------------------------------

The concepts of drug promiscuity ([@bib42]; [@bib59]) and polypharmacology ([@bib70]; [@bib67]) denote the effects of a drug on multiple targets, usually with an assumption of direct binding to the target proteins. Our results, together with those in earlier studies ([@bib38]; [@bib54]; [@bib14]; [@bib40], [@bib41]; [@bib71]), suggest an alternative mechanism for drug promiscuity/polypharmacology for membrane proteins, namely that the drug in question alters the physical properties of the common feature among all membrane proteins: their host lipid bilayer. Amiodarone and dronedarone alter bilayer properties at clinically relevant concentrations and alter the function of multiple membrane proteins, suggesting that their promiscuity, and maybe even their clinical effects, may be due, at least in part, to their effects on the lipid bilayer, thus representing a novel form of polypharmacology. Although the list of protein targets for amiodarone and dronedarone is effectively the same, dronedarone's efficacy is disputable and, considering its low bioavailability ([@bib34]) compared with amiodarone ([@bib48]), pharmacokinetics may play an important role in the differences in efficacy between these two drugs.

Many other current drugs similarly exhibit multichannel effects ([@bib35]), and some drug targets, such as Na~V~1.5, are mechanosensitive ([@bib60]; [@bib12]). For example, ranolazine, a novel multichannel antiarrhythmic ([@bib35]), reduces the mechanosensitivity of Na~V~1.5 channels in mouse cardiomyocytes, which may be caused by changes in lipid bilayer properties ([@bib13]), as well as the shear-stretch sensitivity of endogenous voltage-dependent currents in cell lines derived from human atrial myocytes ([@bib78]). ([Table 2](#tbl2){ref-type="table"} in [@bib60] summarizes drug effects on a variety of Na~V~ channels.) We have previously found a correlation between drug off-target effects and bilayer-modifying potency in a family of insulin-sensitizing drugs---the thiazolidinediones---where they altered bilayer properties at the same concentration as their effects on the Na~V~ ([@bib71]). Moreover, the rank order of the bilayer-modifying potency coincided with severity of their side effects, with troglitazone being the most effective but also the most toxic and the most bilayer modifying.

Conclusion
----------

The bilayer-mediated regulation of membrane protein function is fundamentally nonspecific, meaning that drugs that alter bilayer properties will have unintended off-target and pleiotropic effects that may negatively impact their toxicity profiles but also may be beneficial in the case of drugs that alter system properties, such as antiarrhythmics.

Despite the promiscuity that is implicit with a common bilayer-mediated mechanism, the relative changes in the function of any specific protein will depend on the amphiphile-induced changes in $\Delta G_{\text{bilayer}}^{\text{I}\rightarrow\text{II}}$ for that protein. Our results thus suggest that a bilayer-mediated mechanism may explain the ability of antiarrhythmics (and other amphiphilic drugs) to regulate multiple targets within a narrow concentration range. These results furthermore underscore the importance of considering bilayer-mediated effects in drug development as contributing to both beneficial and detrimental off-target and pleiotropic effects.
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